Identification of metabolic pathways underlying FGF1 and CHIR99021-mediated cardioprotection

Bing Xu; Fan Li; Wenjing Zhang; Yajuan Su; Ling Tang; Pengsheng Li; Jyotsna Joshi; Aaron Yang; Dong Li; Zhao Wang; Shu Wang; Jingwei Xie; Haiwei Gu; Wuqiang Zhu

iScience (Jun 2022)

Identification of metabolic pathways underlying FGF1 and CHIR99021-mediated cardioprotection

Bing Xu,
Fan Li,
Wenjing Zhang,
Yajuan Su,
Ling Tang,
Pengsheng Li,
Jyotsna Joshi,
Aaron Yang,
Dong Li,
Zhao Wang,
Shu Wang,
Jingwei Xie,
Haiwei Gu,
Wuqiang Zhu

Affiliations

Bing Xu: Department of Cardiovascular Diseases, Physiology and Biomedical Engineering, Center for Regenerative Medicine, Mayo Clinic Arizona, 13400 E Shea Blvd, Scottsdale, AZ, USA 85259; Department of Cardiology, Northern Jiangsu People’s Hospital, Clinical Medical College, Yangzhou University, Yangzhou 225001, China
Fan Li: Department of Cardiovascular Diseases, Physiology and Biomedical Engineering, Center for Regenerative Medicine, Mayo Clinic Arizona, 13400 E Shea Blvd, Scottsdale, AZ, USA 85259; Department of Kinesiology, South China Normal University, Guangzhou 510631, China
Wenjing Zhang: Center for Translational Science, Department of Cellular Biology and Pharmacology, Herbert Wertheim College of Medicine, Florida International University, Port St. Lucie, FL 34987, USA; College of Health Solutions, Arizona State University, Phoenix, AZ 85287, USA
Yajuan Su: Department of Surgery, University of Nebraska Medical Center, Omaha, NE 68198, USA
Ling Tang: Department of Cardiovascular Diseases, Physiology and Biomedical Engineering, Center for Regenerative Medicine, Mayo Clinic Arizona, 13400 E Shea Blvd, Scottsdale, AZ, USA 85259
Pengsheng Li: Department of Cardiovascular Diseases, Physiology and Biomedical Engineering, Center for Regenerative Medicine, Mayo Clinic Arizona, 13400 E Shea Blvd, Scottsdale, AZ, USA 85259
Jyotsna Joshi: Department of Cardiovascular Diseases, Physiology and Biomedical Engineering, Center for Regenerative Medicine, Mayo Clinic Arizona, 13400 E Shea Blvd, Scottsdale, AZ, USA 85259
Aaron Yang: Department of Cardiovascular Diseases, Physiology and Biomedical Engineering, Center for Regenerative Medicine, Mayo Clinic Arizona, 13400 E Shea Blvd, Scottsdale, AZ, USA 85259
Dong Li: Department of Cardiovascular Diseases, Physiology and Biomedical Engineering, Center for Regenerative Medicine, Mayo Clinic Arizona, 13400 E Shea Blvd, Scottsdale, AZ, USA 85259
Zhao Wang: Department of Diabetes and Cancer Metabolism, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA 91010, USA
Shu Wang: College of Health Solutions, Arizona State University, Phoenix, AZ 85287, USA
Jingwei Xie: Department of Surgery, University of Nebraska Medical Center, Omaha, NE 68198, USA
Haiwei Gu: Center for Translational Science, Department of Cellular Biology and Pharmacology, Herbert Wertheim College of Medicine, Florida International University, Port St. Lucie, FL 34987, USA; College of Health Solutions, Arizona State University, Phoenix, AZ 85287, USA; Corresponding author
Wuqiang Zhu: Department of Cardiovascular Diseases, Physiology and Biomedical Engineering, Center for Regenerative Medicine, Mayo Clinic Arizona, 13400 E Shea Blvd, Scottsdale, AZ, USA 85259; Corresponding author

Journal volume & issue: Vol. 25, no. 6
p. 104447

Abstract

Read online

Summary: Acute myocardial infarction is a leading cause of death worldwide. We have previously identified two cardioprotective molecules — FGF1 and CHIR99021— that confer cardioprotection in mouse and pig models of acute myocardial infarction. Here, we aimed to determine if improved myocardial metabolism contributes to this cardioprotection. Nanofibers loaded with FGF1 and CHIR99021 were intramyocardially injected to ischemic myocardium of adult mice immediately following surgically induced myocardial infarction. Animals were euthanized 3 and 7 days later. Our data suggested that FGF1/CHIR99021 nanofibers enhanced the heart’s capacity to utilize glycolysis as an energy source and reduced the accumulation of branched-chain amino acids in ischemic myocardium. The impact of FGF1/CHIR99021 on metabolism was more obvious in the first three days post myocardial infarction. Taken together, these findings suggest that FGF1/CHIR99021 protects the heart against ischemic injury via improving myocardial metabolism which may be exploited for treatment of acute myocardial infarction in humans.

Published in iScience

ISSN: 2589-0042 (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Science
Website: http://www.cell.com/iscience/home

About the journal

Abstract

Keywords